Merck-Moderna mRNA Vaccine Succeeds in Melanoma Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck and Moderna reported success of their personalized mRNA neoantigen cancer therapy in a late-stage melanoma clinical trial
- Revolution Medicines achieved success earlier this spring with a KRAS-targeted drug, cited alongside Merck/Moderna as a 2026 oncology milestone
- The author characterizes 2026 as potentially "one of the most consequential years in cancer treatment, ever" based on the convergence of these two breakthroughs
- The Merck/Moderna therapy uses a personalized mRNA neoantigen vaccine approach — a vaccine-style strategy that trains the immune system against tumor-specific antigens
- The story first appeared in STAT+'s subscriber-only "Adam's Biotech Scorecard" newsletter, with the full article gated behind a paywall
Why it matters: Two precision oncology milestones landed in 2026 — Merck/Moderna's personalized mRNA neoantigen vaccine in melanoma and Revolution Medicines' KRAS-targeted drug — which the source argues elevates this year to potentially the most consequential in cancer treatment history, with both approaches targeting specific molecular vulnerabilities rather than broad chemotherapy.
Ask SkimNews
